KR100472964B1 - Fermentative ginseng containing Bacterial hydrolyzing ginseng saponin and its manufacturing method. - Google Patents

Fermentative ginseng containing Bacterial hydrolyzing ginseng saponin and its manufacturing method. Download PDF

Info

Publication number
KR100472964B1
KR100472964B1 KR10-2002-0046668A KR20020046668A KR100472964B1 KR 100472964 B1 KR100472964 B1 KR 100472964B1 KR 20020046668 A KR20020046668 A KR 20020046668A KR 100472964 B1 KR100472964 B1 KR 100472964B1
Authority
KR
South Korea
Prior art keywords
ginseng
fermented
lactobacillus
saponin
lactobacilus
Prior art date
Application number
KR10-2002-0046668A
Other languages
Korean (ko)
Other versions
KR20040013653A (en
Inventor
히데오 하세가와
김재백
Original Assignee
김재백
히데오 하세가와
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김재백, 히데오 하세가와 filed Critical 김재백
Publication of KR20040013653A publication Critical patent/KR20040013653A/en
Application granted granted Critical
Publication of KR100472964B1 publication Critical patent/KR100472964B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00Preparation of steroids
    • C12P33/20Preparation of steroids containing heterocyclic rings
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/10Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof

Abstract

인삼성분인 배당체(saponin)성분을 분해하여 사포닌분해물, 즉 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol 중 적어도 하나를 함유하는 것을 특징으로 하는 발효인삼을 제공하는 것이다. 인삼을 미생물로 발효하여 얻어진 발효인삼으로 이 발효인삼 중에는 사포닌분해물, 즉 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol 중 적어도 하나의 성분을 함유하는 것을 특징으로 하는 발효인삼 및 사포닌분해능을 갖는 미생물을 인삼에 접종, 배양하는 상기 발효인삼의 제조방법을 제공한다.Degradation of saponin, a ginseng component, of saponin digests, namely 20 (S) -protopanaxadiol 20-O- It provides a fermented ginseng, characterized in that it contains at least one of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol. A fermented ginseng obtained by fermenting ginseng as a microorganism. Among these fermented ginsengs, saponin degradation products, 20 (S) -protopanaxadiol 20-O- -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol fermented ginseng, characterized in that it contains at least one of the components and saponin-degrading microorganisms inoculated in ginseng, the production of the fermented ginseng Provide a method.

Description

사포닌분해물을 함유하는 발효인삼 및 그 제조방법{Fermentative ginseng containing Bacterial hydrolyzing ginseng saponin and its manufacturing method.}Fermented ginseng containing saponin lysate and its manufacturing method {Fermentative ginseng containing Bacterial hydrolyzing ginseng saponin and its manufacturing method.}

(발명에 속하는 기술분야)(Technology belonging to the invention)

이 발명은 인삼을 미생물로 발효할 때 얻어지는 발효인삼으로 이 발효인삼 중에는 사포닌분해물, 즉 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol 중 적어도 하나를 함유하는 것을 특징으로 하는 발효인삼 및 그의 제조방법을 제공하는 것이다.The present invention is a fermented ginseng obtained when fermenting ginseng as a microorganism. Among these fermented ginsengs, saponin degradants, namely 20 (S) -protopanaxadiol 20-O- It provides a fermented ginseng and a method for producing the same, comprising at least one of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol.

(종래기술)(Prior Art)

인삼은 다양한 효능 때문에 고래로부터 만능약으로 쓰여져 왔다. 그런데 인삼 중의 유효성분인 사포닌은 glucose, arabinose, rhamnose 등과 결합된 배당체로서 경구섭취 후 생체소화효소에 의하여 거의 분해되지 않고 (Hasegawa H., et al., Microbial Ecology in Health and Disease, 12, 85-91, 2000) 오로지 장내세균에 의하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol로 분해된 후 흡수된다.(Hasegawa H., et al., Planta Medica, 62, 453-457, 1996)Ginseng has been used as a universal medicine from whales because of its various effects. However, saponin, an active ingredient in ginseng, is a glycoside combined with glucose, arabinose, and rhamnose, and is hardly degraded by biodigestive enzymes after oral intake (Hasegawa H., et al., Microbial Ecology in Health and Disease, 12, 85- 91, 2000) 20 (S) -protopanaxadiol 20-O- by enterobacteriaceae It is digested with -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol and then absorbed (Hasegawa H., et al., Planta Medica, 62, 453-457, 1996).

그런데 장내세균의 구성은 개인차가 크므로 사포닌의 흡수는 개인차에 따라 달라질 수 있다. 발명자는 사포닌분해능이 약효에 영향을 미치는 점을 마우스를 이용하여 암전이 실험으로 분명히 하였다.(Hasegawa H., et al., Planta Medica, 64, 696-700, 1998) 아울러 발명자는 실제로 사람에 있어서도 사포닌분해능에서 개체차가 상당히 크다는 것도 확인했다.(Hasegawa H., et al., Planta Medica, 63, 436-440, 1997)However, since the composition of the intestinal bacteria is large individual differences, the absorption of saponin may vary depending on the individual differences. The inventors clarified the effect of saponin degradability on the drug metabolism experiments using mice (Hasegawa H., et al., Planta Medica, 64, 696-700, 1998). It was also confirmed that the individual differences in saponin resolution were quite large (Hasegawa H., et al., Planta Medica, 63, 436-440, 1997).

장내세균은 체질 및 식생활의 영향을 받기 쉽고 따라서 개체차가 크고 또한 민족차에 있어서는 더욱 현저하다. 이와같은 점이 인삼의 치료현장에서 경험하는 약효의 개체차의 하나의 원인이 될 수 있다는 것을 용이하게 상상할 수 있다.Enterobacteriaceae are susceptible to constitution and diet, and therefore have large individual differences and are more prominent in ethnic teas. It can be easily imagined that this may be one cause of individual differences in the effects of ginseng treatment at the treatment site.

위와같은 이유로 발명자는 미리 장내세균을 이용하여 사포닌분해물을 생체외에서 제조하고 장내세균에 의한 개체차의 영향을 배제한 형태로 제공하는 것을 가능하게 하였다.(특개평 10-99094호 공보, 미국특허 제 5925537호)For this reason, the inventors have previously made it possible to prepare saponin digests in vitro using intestinal bacteria in a form that excludes the effects of individual differences caused by the intestinal bacteria (see Japanese Patent Application Laid-Open No. 10-99094, US Patent No. 5925537). number)

그 제조방법에는 사포닌분해물의 생성율에는 문제가 없으나 부차반응에 의한 장내세균 특유의 냄새물질을 포함한 대사물이 생성될 수 있으므로 생성 사포닌분해물을 배양배지에서 분리, 정제할 필요가 있으며 그대로는 식용으로 공급할 수가 없는 난점이 있다. 이 제조방법의 목적은 사포닌분해물 및 배양배지를 포함한 형태대로 식용 가능케 하는 것이며 맛이나 냄새, 물성, 작업성 등에서 더욱 수월한 발효인삼을 제공하는 것이다.The production method has no problem in the production rate of saponin degradation products, but since the metabolites including odorous substances specific to intestinal bacteria can be produced by secondary reactions, it is necessary to separate and purify the produced saponin degradation products from the culture medium. There is a difficulty. The purpose of this manufacturing method is to make it edible in the form including saponin degradation product and culture medium, and to provide fermented ginseng that is easier in taste, smell, physical properties, workability, and the like.

발명자 등은 상기과제를 해결할 수 있는 여러 미생물을 예로 검색한 결과 식용으로 공급되는 효모, 유산균, Bifidobacterium속세균 등에서 인삼을 발효함과 동시에 사포닌을 분해하는 능력(이하「사포닌분해능」이라 함)을 갖는 미생물을 발견하고 이 미생물을 사용하면 사포닌분해물을 함유한 발효인삼을 제조할 수 있음을 확인하고 이 발명을 완성하였다.The inventors have searched for various microorganisms that can solve the above problems as an example, and as a result of fermenting ginseng in yeast, lactic acid bacteria, Bifidobacterium bacteria, etc. supplied for food, and having the ability to decompose saponins (hereinafter referred to as "saponin degradability") The discovery of the microorganism and the use of this microorganism confirmed that it was possible to prepare fermented ginseng containing saponin degradation products and completed the present invention.

즉 이 발명은 인삼을 미생물로 발효하여 얻은 발효인삼 중에는 사포닌분해물 20(S)-protopanaxdiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol 중 적어도 하나를 함유하는 것을 특징으로 하는 발효인삼을 제공하는 것이다.That is, in the fermented ginseng obtained by fermenting ginseng as a microorganism, saponin digest 20 (S) -protopanaxdiol 20-O- It provides a fermented ginseng, characterized in that it contains at least one of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol.

더욱 이 발명은 사포닌분해능을 갖는 미생물을 인삼에 접종하여 배양하는 것을 특징으로 하는 발효인삼의 제조방법을 제공하는 것이다.The present invention further provides a method for preparing fermented ginseng, which is characterized by inoculating microorganisms having saponin-degrading capacity into ginseng.

이 발명에 있어서 발효인삼이란 인삼에 유산균이나 Bifidobacterium속세균 등의 미생물을 접종하여 발효한 것을 말한다. 원료로 사용되는 인삼은 수확 후 물로 세척한 것 또는 건조한 것 혹은 증자하여 건조한 것을 분말로 한 것을 말할 수 있다. 원료로 사용하는 인삼은 주성분으로 사포닌을 함유하는 인삼을 칭하며 고려인삼(Korea ginseng:Panax ginseng C. A. Meyer), 삼칠인삼(Sanchi ginseng:Panax notoginseng(burk.) F. H. Chen), 미국인삼(American ginseng:Panax quinquefolium L.), 죽절인삼(Chikusetsu ginseng:Panax japonicus C. A. Meyer), 히말라야인삼 (Himalayan ginseng:Panax pseudo-ginseng Wall.subsp.himalaicus Hara) 및 베트남인삼(Vietnamese ginseng:Panax vietnamensis Ha et Grushv.) 등을 들 수 있으나 이들 인삼에만 한정하지 않는다. 아울러 이들 인삼은 단독으로 혹은 이들을 조합하여 사용할 수 있다. 이 발명의 발효인삼은 발효인삼 중에 사포닌분해물 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol 중 적어도 하나를 함유하는 것이고, 예를들면 인삼발효를 사포닌분해능이 있는 미생물을 이용해 제조한다. 이 발효에 있어서는 사포닌분해능이 있는 미생물을 단독으로 혹은 몇 종류를 조합하여 사용할 수 있다.In the present invention, fermented ginseng refers to the fermented ginseng by inoculating microorganisms such as lactic acid bacteria and Bifidobacterium genus bacteria. Ginseng used as a raw material may be washed with water after harvesting or dried or powdered dried. The ginseng used as a raw material refers to ginseng containing saponin as its main ingredient, Korean ginseng (Panax ginseng CA Meyer), Sanchi ginseng: Panax notoginseng (burk.) FH Chen, American ginseng (Panax) quinquefolium L.), Chokusetsu ginseng: Panax japonicus CA Meyer, Himalayan ginseng: Panax pseudo-ginseng Wall.subsp.himalaicus Hara, and Vietnamese ginseng: Panax vietnamensis Ha et Grushv. But not limited to these ginseng. In addition, these ginseng can be used individually or in combination. Fermented ginseng of the present invention is saponinate 20 (S) -protopanaxadiol 20-O- in fermented ginseng It contains at least one of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol. For example, ginseng fermentation is prepared using microorganisms capable of saponin degrading. In this fermentation, microorganisms having saponin-degrading ability can be used alone or in combination of several kinds.

이들 미생물 중 어떤 미생물이 사포닌분해능이 있는가의 유무는 예를들면 고압가열살균(121℃, 15분간)한 인삼에 미생물을 접종하여 발효한 발효인삼 중 사포닌분해물, 즉 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol을 박층크로마토그래피법(Hasegawa H., et al., Planta Medica, 62, 453-457, 1996)으로 확인할 수 있다.The presence or absence of any microorganisms among these microorganisms can be determined by, for example, saponin degradation products, 20 (S) -protopanaxadiol 20- in fermented ginseng fermented by inoculating microorganisms into ginseng under high pressure heating sterilization (121 ° C, 15 minutes). O- -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol can be identified by thin layer chromatography (Hasegawa H., et al., Planta Medica, 62, 453-457, 1996).

이 발명의 발효인삼의 제조에 있어서 사포닌분해능이 있는 미생물(이하「사포닌분해미생물」이라 말함)로서 사용하는 미생물은 식품에 첨가할 수 있는 -glucosidase, -arabinosidase, -rhamnosidase 생성균이면 제한하지 않으며 Lactobacillus acidphilus, L.gasseri, L.mali, L.plantarum, L.buchneri, L.casei, L.plantarum, L.johnsonii, L.gallinarum, L.amylovorus, L.brevis, L.rhamnosus, L.kefir, L.paracasei, L.crispatus 등의 Lactobacillus속세균, Streptococcus thermophilus 등의 Streptococcus속세균, Lactococcus lactis 등의 Lactococcus속세균, Bifidobacterium bifidum, B.longum, B.adoloscontis, B.infantis, B.breve, B.catenulatum 등의 Bacillus속세균, Saccharomyses cerevisiae, Torulaspora delbrueckii, Candida kefir 등의 Saccharomyses속, Torulaspora속, Candida속 등에 속하는 효모들 중 앞에 기술한 방법으로 사포닌분해능을 가진다고 판단된 미생물을 들 수 있다.In the preparation of the fermented ginseng of the present invention, microorganisms used as saponin-degrading microorganisms (hereinafter referred to as saponin-degrading microorganisms) can be added to food. -glucosidase, -arabinosidase, It is not limited to -rhamnosidase producing bacteria, and it is not limited to Lactobacillus acidphilus, L.gasseri, L.mali, L.plantarum, L.buchneri, L.casei, L.plantarum, L.johnsonii, L.gallinarum, L.amylovorus, L.brevis, Lactobacillus genus such as L.rhamnosus, L. kefir, L. paracasei, L. crispatus, Streptococcus genus such as Streptococcus thermophilus, Lactococcus genus such as Lactococcus lactis, Bifidobacterium bifidum, B.longum, B.adoloscontis, B. Among the yeasts belonging to Bacillus genus such as infantis, B.breve and B.catenulatum, Saccharomyses cerevisiae, Torulaspora delbrueckii, Candida kefir, Saccharomyses, Torulaspora, Candida, etc. Can be mentioned.

이 중에서도 Lactobacillus속, Streptococcus속, Lactococcus속에 속하는 유산균, Bifidobacterium속세균이나 Saccharomyses속세균이 사포닌분해물의 생성량이나 발효인삼의 맛과 냄새가 적절하고 특히 Lactobacillus.gasseri DSM2024주, Lactobacillus.plantarum ATCC14947주 및 ATCC10241주, L.buchneri ATCC4005주, L.gasseri ATCC393주, L.mail ATCC27304주, L.gallinarum JCM2011주, L.amylovorus JCM1126주, L.brevis ATCC14869주, L.rhamnosus ATCC7469주 및 ATCC53103주, L.kefir NRIC1693주, L.paracasei NCDO-151주, Lactococcus.lactis ATCC15577주, Bifidobacterium.bifidum JCM7002주, B.adolescentis ATCC15703주, Saccharomyses.cerevisiae IFO-0309주 및 IFO-2018주는 -glucosidase, -arabinosidase, -rhamnosidase 활성이 특히 높기 때문에 바람직하다. 또한 1종의 사포닌분해미생물에서 이 발명의 발효인삼을 얻을 수 있지만 일반적으로 2종 이상을 조합하여 사용하는 쪽이 배양시간을 단축할 수 있기 때문에 바람직하다. 이 발명의 발효인삼 제조는 사포닌분해미생물을 사용하는 것 이외에는 일반적인 방법을 따른다. 예를들면 먼저 인삼을 살균처리 후 사포닌분해미생물을 접종하여 배양한 다음 이것을 균질화처리하여 발효인삼을 얻을 수 있다. 인삼발효는 사포닌분해미생물을 2종 이상 조합하여 접종하고 배양발효할 경우에는 혐기성균이면 배양기 중의 산소를 탄산가스나 질소가스 등의 불활성가스로 치환하거나 또는 산소반응제 등으로 제산소하고 혐기적 조건하에 배양할 수도 있다. 호기성균이면 산소 존재하의 호기조건을 선택한다. 더욱더 상기의 2종 이상의 미생물을 동시에 접종하고 배양할 수도 있으며 각각 접종하여 배양할 수도 있다. 한편 인삼을 발효할 때의 조건은 이용하는 미생물의 종류에 따라 설정한다.Among these, Lactobacillus, Streptococcus, Lactococcus, Lactobacillus, Bifidobacterium, and Saccharomyses are the most suitable for the production of saponin degradation products and the taste and smell of fermented ginseng. , L.buchneri ATCC4005, L.gasseri ATCC393, L.mail ATCC27304, L.gallinarum JCM2011, L.amylovorus JCM1126, L.brevis ATCC14869, L.rhamnosus ATCC7469 and ATCC53103, L.kefir NRIC1693 L.paracasei NCDO-151, Lactococcus.lactis ATCC15577, Bifidobacterium.bifidum JCM7002, B.adolescentis ATCC15703, Saccharomyses.cerevisiae IFO-0309 and IFO-2018 -glucosidase, -arabinosidase, -rhamnosidase activity is preferred because it is particularly high. In addition, although the fermented ginseng of the present invention can be obtained from one saponin-degrading microorganism, it is generally preferable to use two or more kinds in combination to shorten the culture time. Fermented ginseng preparation of the present invention follows a general method except using saponin-degrading microorganisms. For example, first, the ginseng can be sterilized and inoculated with saponin-degrading microorganisms, followed by homogenization, to obtain fermented ginseng. Ginseng fermentation is inoculated with a combination of two or more saponin-degrading microorganisms, and when fermentation is anaerobic, if it is anaerobic, the oxygen in the incubator is replaced with an inert gas such as carbon dioxide or nitrogen gas, or it is oxidized with an oxygen-reactive agent and anaerobic conditions. It can also be cultured under. For aerobic bacteria, aerobic conditions in the presence of oxygen are selected. Furthermore, two or more of the above microorganisms may be inoculated and cultured at the same time, or each may be inoculated and cultured. Meanwhile, conditions for fermenting ginseng are set according to the type of microorganism used.

예를들면 유산균, Bifidobacterium속세균이나 Saccharomyses속세균을 이용하는 경우에는 25℃-37℃에서 24-48시간정도 배양하는 것이 좋고, 인삼농도는 고형분을 기준으로 1%-50%가 사포닌분해물 생성량으로 바람직하다. 이 경우의 배양발효할 때 원료인 인삼에 각종 당질 등 예를들면 쌀겨, 옥수수, 전분일 경우는 10%-30%정도 포도당, 서당, 과당, 유당 등이면 0.5%-5.0%정도 첨가한다. 상기와 같이 시행하여 얻은 발효인삼은 그대로 제품화 할 수 있지만 일반적으로는 풍미를 올리거나 맛과 냄새가 좋은 제품을 만들기 위해 여러가지의 성분을 첨가, 배합하고 더 나아가 후레이바를 첨가하여 최종제품으로 할 수 있다.For example, when lactic acid bacteria, Bifidobacterium bacteria or Saccharomyses bacteria are used, it is preferable to incubate at 24-48 hours at 25 ℃ -37 ℃, and the ginseng concentration is preferably 1% -50% based on the solid content as saponin degradation product. Do. In this case, when fermentation of fermented ginseng, various sugars such as rice bran, corn, and starch are added in the range of about 10% -30% for glucose, sucrose, fructose, and lactose. Fermented ginseng obtained by the above-mentioned process can be commercialized as it is, but in general, various ingredients can be added and blended in order to increase flavor or make a product with good taste and smell, and furthermore, it can be added as a final product. have.

이 발명의 발효인삼에 첨가, 배합하는 성분으로서는 각종 당질이나 유화제, 감미료, 산미료, 과즙 등을 들 수 있다. 보다 구체적으로는 포도당, 서당, 과당, 봉밀 등의 당질 솔비톨, 키실리톨, 에레스리톨, 락티톨, 파라티니드 등의 당알코올, 서당지방산에스텔, 글리세린지방산에스텔, 레시틴 등의 유화제를 들 수 있다.Examples of the component to be added and blended with the fermented ginseng of the present invention include various sugars, emulsifiers, sweeteners, acidulants and fruit juices. More specifically, sugar alcohols such as saccharide sorbitol such as glucose, sucrose, fructose and beeswax, sugar alcohols such as xylitol, erythritol, lactitol and paratinide, and sucrose fatty acid ester, glycerin fatty acid ester and lecithin have.

이외에도 비타민A, 비타민B류, 비타민C, 비타민E 등의 각종 비타민류나 식물엑기스, 곡물성분, 야채성분, 젖성분 등을 배합하여도 수월한 냄새와 맛을 지닌 발효인삼을 제조할 수 있다. 또 이 발명의 발효인삼에 첨가 가능한 것은 요그르트계, 베리계, 오렌지계, 모과나무계, 사과계, 민트계, 포도계, 카스타드크림, 복숭아, 멜론, 바나나트로피컬, 허브, 홍차, 커피 등을 들 수 있고, 이것들을 1종류 또는 2종 이상 조합하여 사용할 수 있다. 후레이바의 첨가량은 한정되지 않지만 0.05%-0.5% 특히 0.1%-0.3%정도가 바람직하다. 이상 설명한 이 발명의 발효인삼은 고형상, 액상 등 어떤 형태의 제품이라도 제조가능하다. 또 발효종료 후 발효인삼에 살균처리를 시행하고 사균함유제품도 제조할 수 있다.In addition, it is possible to prepare fermented ginseng with an easy smell and taste even by combining various vitamins such as vitamin A, vitamin B, vitamin C, vitamin E, plant extracts, grain components, vegetable components, and milk components. The fermented ginseng of the present invention can be added to yogurt, berry, orange, quince, apple, mint, grape, custard cream, peach, melon, banana tropical, herbs, tea, coffee, etc. These can be used 1 type or in combination of 2 or more types. Although the addition amount of the flavor is not limited, 0.05% -0.5% especially 0.1% -0.3% is preferable. Fermented ginseng of the present invention described above can be produced in any form of product, such as a solid, liquid. After fermentation, fermented ginseng can be sterilized and sterilized products can be prepared.

(실시예)(Example)

다음의 실시예 및 참고예를 서술하고 발명을 더욱더 상세하게 설명하지만 이 발명은 실시예 등에 하등 제약되는 것이 아니다. 다음의 실시예에 있어서 사포닌분해물의 정성은 이 발명자들의 방법에(Planta Medica, 62, 453-457, 1996) 따르고 박층크로마토그래피(TLC)법으로 시행하였다.The following Examples and Reference Examples are described and the invention is described in more detail, but the invention is not limited to the Examples and the like. In the following examples, the saponinated product was subjected to the method of the inventors (Planta Medica, 62, 453-457, 1996) and performed by thin layer chromatography (TLC).

발효인삼시료 약 1g을 칭량하여 여기에 물2ml와 수포화 n-부탄올 1ml를 가하여 추출한다. 이 추출액을 원심분리(3000rpm, 10분간)하여 얻어진 상층액 2ul를 TLC에 점적한다. 동시에 사포닌분해물 표준물질로서 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol도 점적한다. TLC혼합용매(CHCl3-methanol-물 60:35:10, 하층)로 전개하여 TLC plate에 8% 바닐린 methanol / 72% 황산용액(1:5용적비)를 분무한 다음 가열(140℃, 3분)하여 적자색을 나타내는 반점을 검출한다. 사포닌분해물 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 Rf값은 각각 0.63, 0.70 및 0.83이었다.Approximately 1 g of fermented ginseng sample is weighed and extracted by adding 2 ml of water and 1 ml of saturated n-butanol. 2 ul of the supernatant obtained by centrifugation (3000 rpm, 10 minutes) of this extract was added dropwise to TLC. At the same time, 20 (S) -protopanaxadiol 20-O- as a saponin digest standard D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol are also spotted. Expanded with TLC mixed solvent (CHCl 3 -methanol-water 60:35:10, lower layer), sprayed 8% vanillin methanol / 72% sulfuric acid solution (1: 5 volume ratio) on TLC plate, and heated (140 ° C, 3 minutes). To detect red spots. Saponinate 20 (S) -protopanaxadiol 20-O- Rf values of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol were 0.63, 0.70 and 0.83, respectively.

(실시예1: 발효고려인삼의 제조)Example 1 Preparation of Fermented Korean Ginseng

고려인삼(대한민국산, 건조3년근)의 분말 200g을 정제수 400ml에 현탁하여 고압가압살균(121℃, 15분간)한 다음 Lactobacillus rhamnose ATCC7469주를 1%접종하여 37℃, 7일간 배양한다. 발효배지를 TLC법으로 분석하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 생성을 확인하였다. 80도에서 6시간 건조하여 발효인삼(170g)을 얻을 수 있다.200 g of Korean ginseng (Korean, dried 3 years old) was suspended in 400 ml of purified water and sterilized by autoclaving (121 ° C, 15 minutes), and then incubated with 1% of Lactobacillus rhamnose ATCC7469 strain at 37 ° C for 7 days. The fermentation broth was analyzed by TLC method to determine 20 (S) -protopanaxadiol 20-O- The production of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol was confirmed. It is dried for 6 hours at 80 degrees to obtain fermented ginseng (170g).

(참고예1)Reference Example 1

사지냉증을 호소하는 여성 40인을 무작위로 20명씩 2군으로 나누어 이중맹검법으로 내용물이 보이지 않는 캅셀에 비발효인삼 및 실시예1에서 제조한 발효인삼을 1일 3g, 1주간 투여하였다. 이 결과 냉증이 개선된 유효율은 비발효인삼의 경우 45%인데 비하여 발효인삼의 경우 85%의 유효율을 나타내었다.Forty women who complained of cold limbs were randomly divided into two groups of 20 people, and the fermented ginseng prepared in Example 1 and 3 g per day were administered to capsules in which the contents were not visible by the double-blind method. As a result, the effective rate of cold improvement was 45% for non-fermented ginseng, and 85% for fermented ginseng.

(실시예2: 발효홍삼의 제조)Example 2 Preparation of Fermented Red Ginseng

홍삼(대한민국정관압제)의 분말 200g을 정제수 400ml에 현탁하여 고압가압살균(121℃, 15분간)한다. Bifidobacterium adolescentis ATTCC15703주를 1%접종하여 37℃, 7일간 배양한다. 발효배지를 TLC법으로 분석하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 생성을 확인하였다. 80도에서 6시간 건조하여 발효인삼(165g)을 얻을 수 있다.200 g of red ginseng (Korean tube pressure agent) is suspended in 400 ml of purified water and sterilized under high pressure (121 ° C., 15 minutes). 1% of Bifidobacterium adolescentis ATTCC15703 was inoculated and incubated at 37 ° C for 7 days. The fermentation broth was analyzed by TLC method to determine 20 (S) -protopanaxadiol 20-O- The production of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol was confirmed. It is dried for 6 hours at 80 degrees to obtain fermented ginseng (165g).

삭제delete

(참고예 2)(Reference Example 2)

어깨결림을 호소하는 여성 40인을 무작위로 20명씩 2군으로 나누어 이중맹검법으로 내용물이 보이지 않는 캅셀에 비발효인삼 및 실시예2에서 제조한 발효인삼을 1일 3g, 1주간 투여하였다. 이 결과 어깨결림이 개선된 유효율은 비발효인삼의 경우 35%인데 비하여 발효인삼의 경우 70%의 유효율을 나타내었다.Forty females complaining of stiff shoulders were randomly divided into two groups of 20 people, and the fermented ginseng prepared in Example 2 and the fermented ginseng prepared in Example 2 were administered to capsules in which the contents were not visible by the double-blind method. As a result, the effective rate of improved shoulder stiffness was 35% for non-fermented ginseng, and 70% for fermented ginseng.

이상의 참고예는 발효인삼의 즉효성을 시사하는 것이다. 이것은 인삼의 발효처리로 사포닌대사물의 흡수율이 증가하였던 것에 기인하는 것으로 생각된다.The above reference suggests an immediate effect of fermented ginseng. This is thought to be due to the increase in the absorption rate of saponin metabolites by the fermentation treatment of ginseng.

(실시예3: 발효미국인삼의 제조)Example 3 Preparation of Fermented American Ginseng

미국인삼의 분말 200g을 정제수 400ml에 현탁하여 고압가압살균(121℃, 15분간)한다. Lactobacillus gasseri DSM20243주를 1%접종하여 37℃, 7일간 배양한다. 발효배지를 TLC에 분석하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 생성을 확인하였다. 80도에서 6시간 건조하여 발효인삼(160g)을 얻을 수 있다.200 g of American ginseng powder is suspended in 400 ml of purified water and sterilized under high pressure (121 ° C., 15 minutes). Inoculate 1% of Lactobacillus gasseri DSM20243 strain and incubate at 37 ° C. for 7 days. Fermentation broth was analyzed by TLC and 20 (S) -protopanaxadiol 20-O- The production of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol was confirmed. It is dried for 6 hours at 80 degrees to obtain fermented ginseng (160g).

삭제delete

삭제delete

(실시예4: 발효삼칠인삼의 제조)Example 4 Preparation of Fermented Ginseng Ginseng

삼칠인삼(중국 운남성산, 4년근)의 분말 200g을 정제수 400ml에 현탁하여 고압가압살균(121℃, 15분간)한다. Bifidobacterium bifidum JCM7002주를 1%접종하여 37℃, 7일간 배양한다. 발효배지를 TLC에 분석하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 생성을 확인하였다. 80도에서 6시간 건조하여 발효인삼(85g)을 얻을 수 있다.200 g of the powder of Samchil ginseng (Yunnan Province, China) is suspended in 400 ml of purified water and sterilized under high pressure (121 ℃, 15 minutes). 1% of Bifidobacterium bifidum JCM7002 was inoculated and incubated at 37 ° C. for 7 days. Fermentation broth was analyzed by TLC and 20 (S) -protopanaxadiol 20-O- The production of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol was confirmed. It is dried for 6 hours at 80 degrees to obtain fermented ginseng (85g).

(실시예5: 발효죽절인삼의 제조)Example 5 Preparation of Fermented Bamboo Ginseng

죽절인삼(일본국산, 4년근)의 분말 100g을 정제수 200ml에 현탁하여 고압가압살균(121℃, 15분간)한다. Saccharomyses cerevisiae IFO-0309주를 1%접종하여 37℃, 7일간 배양한다. 발효배지를 TLC법으로 분석하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 생성을 확인한다. 80도에서 6시간 건조하여 발효인삼(88g)을 얻을 수 있다.100 g of powder of bamboo ginseng (Japan, 4 years old) is suspended in 200 ml of purified water and sterilized under high pressure (121 ° C, 15 minutes). Inoculate 1% of Saccharomyses cerevisiae IFO-0309 strain and incubate for 7 days at 37 ° C. The fermentation broth was analyzed by TLC method to determine 20 (S) -protopanaxadiol 20-O- Confirm the production of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol. It is dried for 6 hours at 80 degrees to obtain fermented ginseng (88g).

(실시예6: 발효히말라야인삼의 제조)Example 6 Preparation of Fermented Himalayan Ginseng

히말라야인삼의 분말 100g을 정제수 200ml에 현탁하여 고압가압살균(121℃, 15분간)한다. Saccharomyses cerevisiae IFO-0309주를 1%접종하여 37℃, 7일간 배양한다. 발효배지를 TLC법으로 분석하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 생성을 확인한다. 80도에서 6시간 건조하여 발효인삼(88g)을 얻을 수 있다.100 g of powder of Himalayan ginseng is suspended in 200 ml of purified water and sterilized under high pressure (121 ° C., 15 minutes). Inoculate 1% of Saccharomyses cerevisiae IFO-0309 strain and incubate for 7 days at 37 ° C. The fermentation broth was analyzed by TLC method to determine 20 (S) -protopanaxadiol 20-O- Confirm the production of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol. It is dried for 6 hours at 80 degrees to obtain fermented ginseng (88g).

삭제delete

(실시예7: 발효베트남인삼의 제조)Example 7 Preparation of Fermented Vietnamese Ginseng

베트남인삼(베트남국산, 5년근)의 분말 50g을 정제수 100ml에 현탁하여 고압가압살균(121℃, 15분간)한다. Lactobacillus mali ATCC27304주와 Bifidobacterium bifidum JCM7002주를 각각 1%접종하고 37℃, 7일간 배양한다.50g of Vietnamese ginseng (Vietnam, 5 years old) is suspended in 100ml of purified water and sterilized under high pressure (121 ℃, 15min). Lactobacillus mali ATCC27304 strain and Bifidobacterium bifidum JCM7002 strain were inoculated 1% and incubated at 37 ° C for 7 days.

발효배지를 TLC법으로 분석하여 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol의 생성을 확인한다. 80도에서 6시간 건조하여 발효인삼(46g)을 얻을 수 있다.The fermentation broth was analyzed by TLC method to determine 20 (S) -protopanaxadiol 20-O- Confirm the production of -D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol. It is dried for 6 hours at 80 degrees to obtain fermented ginseng (46g).

삭제delete

상기의 예에서 보는 바와 같이 인삼을 사포닌분해미생물을 발효함으로서 사포닌분해물 20(S)-protopanaxadiol 20-O--D-glucopyranoside, 20(S)-protopanaxadiol 및 20(S)-protopanaxatriol을 함유하는 발효인삼을 제조할 수 있으며 이 발효인삼의 유용성이 혈액개선시험에서 실증되었다.As shown in the above example, saponinate 20 (S) -protopanaxadiol 20-O- was obtained by fermenting saponin-degrading microorganisms with ginseng. Fermented ginseng containing D-glucopyranoside, 20 (S) -protopanaxadiol and 20 (S) -protopanaxatriol can be prepared and its usefulness has been demonstrated in blood improvement tests.

이 발명에 의하면 인삼 중의 유효성분인 사포닌을 미리 발효하여 분해시키므로서 비발효물에 비하여 유용성이 향상된 인삼의 발효식품을 제공할 수 있게 되었다.According to the present invention, it is possible to provide a fermented food of ginseng with improved usefulness compared to non-fermented products by decomposing and decomposing saponin, which is an active ingredient in ginseng, in advance.

아울러 인삼 사포닌의 생체이용율을 증가시키고, 장내세균에 의한 개체차의 영향을 배제한 형태의 발효인삼을 제공하게 되었다.In addition, to increase the bioavailability of ginseng saponin, and to provide a form of fermented ginseng excluding the effects of individual differences caused by intestinal bacteria.

Claims (7)

인삼을 사포닌 분해능이 있는 락토바실러스 람노스 ATCC7469주(Lactobacilus rhamnose ATCC7469), 비피도박테리움 아돌레센티스 ATTCC15703주(Bifidobacterium adolescentis ATTCC15703), 락토바실러스 가세리 DSM20243주(Lactobacillus gasseri DSM20243), 비피도박테리움 비피듐 JCM7002주(Bifidobacterium bifidum JCM7002), 사카로마이세스 세레비지에 IFO-0309주(Saccharomyces cerevisiae IFO-0309), 락토바실러스 말리 ATCC27304(Lactobacilus mali ATCC27304), 락토바실러스 플란타룸 ATCC14947(Lactobacillus plantarum ATCC14947) 또는 락토바실러스 플란타룸 ATCC10241(Lactobacillus plantatum ATCC10241)로 이루어진 군으로부터 선택된 1종 이상의 미생물로 발효할 때 얻어지는 발효인삼으로 해당 발효인삼 중에 사포닌분해물 20(S)-protopanaxadiol 또는 20(S)-protopanaxatriol를 포함하는 것을 특징으로 하는 발효인삼.Lactobacilus rhamnose ATCC7469 (Lactobacilus rhamnose ATCC7469), Bifidobacterium adolescents ATTCC15703 (Bifidobacterium adolescentis ATTCC15703), Lactobacillus gasteria DSM20243 43 (Lactobacillus bacterium) Bifidobacterium bifidum JCM7002, Saccharomyces cerevisiae IFO-0309, Lactobacilus mali ATCC27304, Lactobacilus plantarum ATCC14947 plant or Lactoba ATcillus AT47 A fermented ginseng obtained by fermentation with one or more microorganisms selected from the group consisting of Lactobacillus plantatum ATCC10241 (Lactobacillus plantatum ATCC10241). Fermented ginseng, characterized in that. 삭제delete 삭제delete 제1항에 있어서, 상기 인삼은 고려인삼, 삼칠인삼, 미국인삼, 죽절인삼, 히말라야인삼 및 베트남인삼 중에서 선택되는 발효인삼.The ginseng of claim 1, wherein the ginseng is selected from Korean ginseng, Samchil ginseng, American ginseng, bamboo shoot ginseng, Himalayan ginseng, and Vietnamese ginseng. 사포닌 분해능이 있는 락토바실러스 람노스 ATCC7469주(Lactobacilus rhamnose ATCC7469), 비피도박테리움 아돌레센티스 ATTCC15703주(Bifidobacterium adolescentis ATTCC15703), 락토바실러스 가세리 DSM20243주(Lactobacillus gasseri DSM20243), 비피도박테리움 비피듐 JCM7002주(Bifidobacterium bifidum JCM7002), 사카로마이세스 세레비지에 IFO-0309주(Saccharomyces cerevisiae IFO-0309), 락토바실러스 말리 ATCC27304(Lactobacilus mali ATCC27304), 락토바실러스 플란타룸 ATCC14947(Lactobacillus plantarum ATCC14947) 또는 락토바실러스 플란타룸 ATCC10241(Lactobacillus plantatum ATCC10241)로 이루어진 군으로부터 선택된 1종 이상의 미생물을 인삼에 접종하고 배양하는 것을 특징으로 하는 발효인삼의 제조방법.Lactobacilus rhamnose ATCC7469 strain with saponin resolution, Bifidobacterium adolescents ATTCC15703 strain, Bifidobacterium adolescentis ATTCC15703 strain, Lactobacillus gasteria DSM20243 strain, Lactobacillus gaspidium dpipidium gaspi Note (Bifidobacterium bifidum JCM7002), Saccharomyces cerevisiae IFO-0309, Lactobacilus mali ATCC27304, Lactobacilus plantarum ATCC14947 (Lactobacillus plantarum) Method of producing a fermented ginseng, inoculated and cultured with one or more microorganisms selected from the group consisting of Planta Room ATCC10241 (Lactobacillus plantatum ATCC10241). 삭제delete 제5항에 있어서, 상기 인삼은 고려인삼, 삼칠인삼, 미국인삼, 죽절인삼, 히말라야인삼 및 베트남인삼 중에서 선택되는 발효인삼의 제조방법The method of claim 5, wherein the ginseng is selected from Korean ginseng, Samchil ginseng, American ginseng, bamboo shoot ginseng, Himalayan ginseng, and Vietnamese ginseng.
KR10-2002-0046668A 2002-07-23 2002-08-07 Fermentative ginseng containing Bacterial hydrolyzing ginseng saponin and its manufacturing method. KR100472964B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002213330A JP3678362B2 (en) 2002-07-23 2002-07-23 Method for producing fermented carrot containing saponin degradation products
JPJP-P-2002-00213330 2002-07-23

Publications (2)

Publication Number Publication Date
KR20040013653A KR20040013653A (en) 2004-02-14
KR100472964B1 true KR100472964B1 (en) 2005-03-10

Family

ID=31935948

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2002-0046668A KR100472964B1 (en) 2002-07-23 2002-08-07 Fermentative ginseng containing Bacterial hydrolyzing ginseng saponin and its manufacturing method.

Country Status (2)

Country Link
JP (1) JP3678362B2 (en)
KR (1) KR100472964B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101083039B1 (en) 2009-11-27 2011-11-16 중앙대학교 산학협력단 Use of Leifsonia sp. GAL45 for preparation of protopanaxatriol
KR20170001397A (en) 2015-06-26 2017-01-04 충남대학교산학협력단 Novel Paenibacillus sp. RMKS 72, fermented ginseng using the same and composition having anti-oxidant activity comprising extract of fermented ginseng using the same

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100496731B1 (en) * 2002-09-26 2005-06-22 (주)휴먼사이언스 Manufacturing process of Ginsenoside and improvement of anti-oxide activity using Phaffia rhodozyma
KR100497895B1 (en) * 2002-12-05 2005-06-29 홍림통산(주) Ginseng fermented by lactic acid bacterium, yoghurt containing the same, and lactic acid bacteria used in the preparation thereof
KR100789261B1 (en) * 2004-12-28 2007-12-31 김재백 A fermented ginseng containing deglycosylated ginsenosides and the preparation method thereof
JP4693623B2 (en) * 2005-03-07 2011-06-01 共栄化学工業株式会社 Cosmetics
JP5483928B2 (en) * 2005-03-07 2014-05-07 共栄化学工業株式会社 Cosmetics
CN100413880C (en) * 2005-03-09 2008-08-27 北京大学 Derivative of protopanoxadiol, prepn. method and application thereof
CN100448886C (en) * 2005-03-09 2009-01-07 北京大学 Derivative of protopanoxatriol, prepn. method and application thereof
KR100813997B1 (en) 2006-09-19 2008-03-14 주식회사 에이치 엔 비티 Processes for preparing jinseng extracts
KR100824285B1 (en) 2006-11-01 2008-04-24 주식회사 에이치 엔 비티 Processes for preparing a saccharified ginseng and ginseng extracts
JP2008255084A (en) * 2007-04-04 2008-10-23 Isako Hashimoto Anti-pollinosis agent or foodstuff
JPWO2008155998A1 (en) * 2007-06-21 2010-08-26 長瀬産業株式会社 Anxiolytic antidepressant
JP5204771B2 (en) * 2007-06-21 2013-06-05 長瀬産業株式会社 GABAergic neuron activator
KR100866504B1 (en) * 2008-09-23 2008-11-11 주식회사 비티씨 Microorganisms for fermentation of red ginseng and food composition containing fermented red ginseng
JP2010132625A (en) * 2008-12-08 2010-06-17 Nagase & Co Ltd Anti-diabetic agent
US8541035B2 (en) 2009-05-14 2013-09-24 Il Hwa Co., Ltd. Methods for preparing a fermented ginseng concentrate or powder
JP6170674B2 (en) * 2009-05-19 2017-07-26 イル・ファ・カンパニー・リミテッドIl Hwa Co.,Ltd. Method for producing fermented ginseng concentrate or powder
KR101593618B1 (en) * 2009-05-26 2016-02-15 (주)아모레퍼시픽 Composition for improving bioavailability of saponin
KR101164529B1 (en) 2010-03-17 2012-07-10 정종배 Ginseng fermentation system for Ginsenoside increase
JP6280398B2 (en) * 2014-03-04 2018-02-14 株式会社ナガセビューティケァ GLP-1 secretion promoter
JP6450878B1 (en) * 2018-03-28 2019-01-09 株式会社ナガセビューティケァ Method for producing fermented product
JP7021752B2 (en) * 2020-02-25 2022-02-17 株式会社機能性食品開発研究所 How to make fermented ginseng
KR102312450B1 (en) * 2020-06-11 2021-10-13 제너럴바이오(주) Composition for prevention or improvement of oral diseases containing ginseng fermented extract and Sophora flavescens extract as an active ingredient
WO2023084839A1 (en) * 2021-11-12 2023-05-19 株式会社皇漢薬品研究所 Method for producing sarcopenia-inhibiting food product, sarcopenia-inhibiting food product, and muscle-enhancing food product

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0523149A (en) * 1991-02-18 1993-02-02 Meiji Milk Prod Co Ltd Fermented beverage of medicinal ginseng extract and its production
KR0178863B1 (en) * 1996-11-29 1999-04-01 김진하 Preparation of Ginseng Saponin Metabolite
KR19990084454A (en) * 1998-05-07 1999-12-06 박명규 Method for preparing ginsenoside aldi by enzymatic method
KR100329259B1 (en) * 1999-03-17 2002-03-20 김봉섭 manufacturing process of ginseng saponins
KR20030065273A (en) * 2002-01-30 2003-08-06 주식회사 일화 Bioconversion ginseng composite using microorganism and fabrication method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0523149A (en) * 1991-02-18 1993-02-02 Meiji Milk Prod Co Ltd Fermented beverage of medicinal ginseng extract and its production
KR0178863B1 (en) * 1996-11-29 1999-04-01 김진하 Preparation of Ginseng Saponin Metabolite
KR19990084454A (en) * 1998-05-07 1999-12-06 박명규 Method for preparing ginsenoside aldi by enzymatic method
KR100329259B1 (en) * 1999-03-17 2002-03-20 김봉섭 manufacturing process of ginseng saponins
KR20030065273A (en) * 2002-01-30 2003-08-06 주식회사 일화 Bioconversion ginseng composite using microorganism and fabrication method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101083039B1 (en) 2009-11-27 2011-11-16 중앙대학교 산학협력단 Use of Leifsonia sp. GAL45 for preparation of protopanaxatriol
KR20170001397A (en) 2015-06-26 2017-01-04 충남대학교산학협력단 Novel Paenibacillus sp. RMKS 72, fermented ginseng using the same and composition having anti-oxidant activity comprising extract of fermented ginseng using the same
KR101718351B1 (en) 2015-06-26 2017-03-21 충남대학교산학협력단 Novel Paenibacillus sp. RMKS 72, fermented ginseng using the same and composition having anti-oxidant activity comprising extract of fermented ginseng using the same

Also Published As

Publication number Publication date
JP3678362B2 (en) 2005-08-03
KR20040013653A (en) 2004-02-14
JP2004049154A (en) 2004-02-19

Similar Documents

Publication Publication Date Title
KR100472964B1 (en) Fermentative ginseng containing Bacterial hydrolyzing ginseng saponin and its manufacturing method.
KR100618171B1 (en) Fermented red ginseng containing ginseng saponin degradate and its manufacturing method
US20200255795A1 (en) Method for preparing microbial preparation and microbial preparation produced by the same
EP3124031B1 (en) Sleep quality improver
TWI465565B (en) Fermentated foods containing bacteria of the genus bifidobacterium and method of preparing the same
KR101370386B1 (en) Preparation method of fermented red ginseng using effective micro-organisms
Yaeshima et al. Effect of Yogurt Containing Bifidobacterium longum BB536 on the Intestinal Environment, Fecal Characteristics and Defecation Frequenc A Comparison with Standard Yogurt
US20230104564A1 (en) Culture process for enhancing proliferation of lactic acid bacteria by using red ginseng
KR101343410B1 (en) Novel Lactobacillus plantarum CRNB-22 (KCTC 11931 BP) strain capable of fermenting ginseng and method of transforming saponin using thereof
JP5505298B2 (en) Helicobacter pylori growth inhibitor and method for producing the same
WO2017047777A1 (en) Serotonin deficiency amelioration agent for after stress-load release
CN101184398A (en) Fermented food containing bifidobacterium bacteria and method for producing the same
JP4354611B2 (en) Fermented soymilk containing isoflavone aglycone and method for producing the same
KR100773059B1 (en) Novel microorganism having deglycosylating ability, the probiotics containing the same and the process for preparing them
JP6110240B2 (en) Lactic acid bacteria, etc., and oral disease prevention materials and foods containing these
Hassanzadeh-Rostami et al. Mixtures of soy-and cow’s milk as potential probiotic food carriers
JP2020061977A (en) Novel lactic acid bacterium that belongs to streptococcus salivarius, and use of the same
KR101324282B1 (en) Preparation method of fermented red ginseng for improving immunity of the human body using effective micro-organisms
KR101343434B1 (en) Novel Enterococcus faecalis CRNB-A3 (KCTC 11930 BP) strain capable of fermenting ginseng and method of transforming saponin using thereof
Elghali et al. Variations on soymilk components during fermentation by Lactobacillus and Bifidobacterium strains
CN111631393B (en) Probiotic fermented product containing turnip and application thereof
CN115153006B (en) Lophatherum gracile fermentation liquor product and preparation method thereof
JP2001333692A (en) Method for producing fermented soybean milk
CN112538439B (en) Lactobacillus plantarum and application thereof in preparing plant coagulated yoghurt and improving intestinal bacterial facies
KR20240029907A (en) Composition for promoting growth of Lactic acid bacteria and a culture medium for Lactic acid bacteria comprising Red Ginseng Oil

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
O035 Opposition [patent]: request for opposition
O133 Decision on opposition [patent]: notification of invalidation of opposition
O132 Decision on opposition [patent]
J210 Request for trial for objection to revocation decision
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION OF CANCELLATION REQUESTED 20061027

Effective date: 20070427

Free format text: TRIAL NUMBER: 2006103000231; TRIAL DECISION FOR APPEAL AGAINST DECISION OF CANCELLATION REQUESTED 20061027

Effective date: 20070427

S901 Examination by remand of revocation
O132 Decision on opposition [patent]
O074 Maintenance of registration after opposition [patent]: final registration of opposition
FPAY Annual fee payment

Payment date: 20121218

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20140204

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20150202

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20160204

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20171127

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20200114

Year of fee payment: 16